Brought to you by 
Zogenix completes $15mm Series C round
10 Sep 2010
Executive Summary
Zogenix Inc. (developing drugs for pain and CNS disorders) raised $15mm in its Series C financing to returning shareholders Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Abingworth Management, and Chicago Growth Partners. Concurrently, the company secured a $35mm debt facility from Oxford Finance and Silicon Valley Bank that consists of a $25mm term loan and $10mm revolving line of credit. The money will enable Zogenix to launch its Sumavel DosePro (sumatriptan) needle-free delivery system for acute migraine and cluster headaches, and to continue Phase III trials of ZX002 for chronic pain.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zogenix completes $15mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice